Treeline Biosciences CSO Jeffrey Engelman (L) and CEO Josh Bilenker

October 17, 2022 09:11 AM EDTUpdated 09:26 AM

Josh Bilenker, Jeff Engelman quiet on everything behind their $735M 'outer edge' startup

Kyle LaHucik

Biotech Correspondent

An $8 billion exit from Eli Lilly and a short-lived stint heading up oncology work at the Big Pharma post-Loxo sale have persuaded Josh …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

RFK Jr. ends annual Covid vaccine recommendations for kids, pregnant women

Biogen taps City Therapeutics in RNAi deal worth up to $1B

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation